Literature DB >> 23509590

Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.

Christine Fukada, Jillian Clare Kohler, Heather Boon, Zubin Austin, Murray Krahn.   

Abstract

OBJECTIVE: The objective of the study was to explore the experiences of physicians prescribing gabapentin off label.
METHODS: We used a case study approach to explore the experiences of physicians prescribing gabapentin for off-label indications. Semi-structured interviews were conducted with 10 physicians (psychiatry, pain and neurology specialists) in the Greater Toronto Area. Data were collected to the point of saturation of key themes and analyzed using interpretive content analysis. KEY
FINDINGS: Key informants appeared to rely primarily on informal information from colleagues and meetings, putting into question the accuracy of their information about the potential off-label uses of gabapentin. Our findings suggest the need for more evidence-based information on off-label drug use.
CONCLUSION: There is a need for greater understanding of off-label prescribing practices as an important step toward improving rational prescribing and ultimately toward improving patient safety and health outcomes.

Entities:  

Year:  2012        PMID: 23509590      PMCID: PMC3567599          DOI: 10.3821/145.6.cpj280

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN: 1715-1635


  17 in total

1.  Off label use--label off use?

Authors:  J Boos
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

2.  Gabapentin may be appropriate for off-label uses.

Authors:  Shawn Davis
Journal:  J Manag Care Pharm       Date:  2003 Nov-Dec

3.  The state of the art versus the state of the science. The diffusion of new medical technologies into practice.

Authors:  A L Greer
Journal:  Int J Technol Assess Health Care       Date:  1988       Impact factor: 2.188

4.  Prescribing for unlabeled indications.

Authors:  J Serradell; B Galle
Journal:  HMO Pract       Date:  1993-03

5.  Satisfaction with pharmacotherapy for approved and off-label indications--a Delphi study.

Authors:  Mitja Kos; Albert I Wertheimer; Ales Mrhar
Journal:  Ann Pharmacother       Date:  2005-03-08       Impact factor: 3.154

6.  Off-label prescribing among office-based physicians.

Authors:  David C Radley; Stan N Finkelstein; Randall S Stafford
Journal:  Arch Intern Med       Date:  2006-05-08

7.  Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure.

Authors:  M H Chin; P D Friedmann; C K Cassel; R M Lang
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

Review 8.  Improving physician prescribing practices: bridge over troubled waters.

Authors:  S M MacLeod
Journal:  CMAJ       Date:  1996-03-01       Impact factor: 8.262

9.  A survey of the off-label use of mood stabilizers in a large psychiatric hospital.

Authors:  Camilla Haw; Jean Stubbs
Journal:  J Psychopharmacol       Date:  2005-07       Impact factor: 4.153

Review 10.  Examination of the evidence for off-label use of gabapentin.

Authors:  Alicia Mack
Journal:  J Manag Care Pharm       Date:  2003 Nov-Dec
View more
  11 in total

1.  Antiepileptic drug use in a nursing home setting: a retrospective study in older adults.

Authors:  Camilla Callegari; M Ielmini; L Bianchi; M Lucano; Lorenza Bertù; Simone Vender
Journal:  Funct Neurol       Date:  2016 Apr-Jun

2.  Attitudes, knowledge and views on off-label prescribing in children among healthcare professionals in Malaysia.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  Int J Clin Pharm       Date:  2019-06-13

Review 3.  Psychiatric Uses of Gabapentin.

Authors:  Jon C Martin; Danielle Gainer
Journal:  Innov Clin Neurosci       Date:  2022 Jul-Sep

4.  Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-12-13

5.  Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities.

Authors:  Sandeep Kumar Gupta; Roopa Prasad Nayak
Journal:  J Pharmacol Pharmacother       Date:  2014-04

6.  Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq.

Authors:  Saad A Hussain; Ashwaq N Abbas; Hasan A Alhadad; Ali A Al-Jumaili; Zainab S Abdulrahman
Journal:  Pharm Pract (Granada)       Date:  2017-08-20

7.  Risk of respiratory depression with opioids and concomitant gabapentinoids.

Authors:  Julie Savelloni; Heather Gunter; Kelly C Lee; Chih Hsu; Cassia Yi; Kyle P Edmonds; Timothy Furnish; Rabia S Atayee
Journal:  J Pain Res       Date:  2017-11-10       Impact factor: 3.133

Review 8.  Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Authors:  Alyssa M Peckham; Kirk E Evoy; Leslie Ochs; Jordan R Covvey
Journal:  Subst Abuse       Date:  2018-09-23

9.  Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance.

Authors:  Alyssa M Peckham; Maria J Ananickal; David A Sclar
Journal:  Risk Manag Healthc Policy       Date:  2018-08-17

10.  Patterns and predictors of off-label prescription of psychiatric drugs.

Authors:  Aishwarya Vijay; Jessica E Becker; Joseph S Ross
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.